Vascular Thromboembolic Disease Thrombectomy Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Vascular Thromboembolic Disease Thrombectomy Market in 2026?

USD 1,193.2 million in 2026 and USD 3,297.6 million by 2036 at a 10.7% CAGR.

Demand for vascular thromboembolic disease thrombectomy is expected to rise at 10.7% CAGR from 2026 to 2036, pushing industry value from USD 1,193.2 million in 2026 to USD 3,297.6 million by 2036. Current thrombectomy systems span venous and arterial procedures alongside neurovascular care that requires different access routes and specialist teams. FDA records dated May and June 2025 document separate clearances for the Symphony and Liberant systems. The regulatory activity supports continued product renewal without proving uniform purchasing across every hospital or disease pathway.

Commercial adoption depends on rapid imaging and appropriate case selection together with reliable transfer into a capable interventional service. Hospitals also need trained clinicians and inventory plans that support emergency procedures outside routine daytime schedules. Demand for blood clot retrieval devices therefore reflects complete pathway readiness rather than device availability alone. Manufacturers gain stronger account access through service coverage and procedural education that reduce delays during urgent clot-removal decisions.

Summary of the Vascular Thromboembolic Disease Thrombectomy Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Time-sensitive vascular emergencies create value for systems that shorten treatment preparation and support predictable clot removal. The market is projected to expand, supported by broader endovascular capability across major hospitals. Clear referral rules help specialist teams identify suitable cases before delays reduce the potential benefit of intervention. Service contracts matter most for systems with consoles or pumps that require dedicated setup steps during emergency procedures.
Product and Segment View	The product structure separates disease pathways from device mechanisms and the procedure used to remove each thrombus. Deep vein thrombosis is estimated to hold 39.6% share in 2026, attributable to established peripheral venous treatment pathways. Aspiration thrombectomy devices are projected to represent 41.3% share in 2026, underpinned by direct clot evacuation workflows. Endovascular thrombectomy and hospitals are forecast to hold 31.5% and 30.2% shares respectively during 2026.
Geography and Growth Outlook	Country growth depends on specialist capacity and the speed of patient transfer into an equipped thrombectomy service. South Korea is projected to record 13.2% CAGR through 2036, strengthened by coordinated cardio-cerebrovascular care expansion. Germany is forecast to post 10.9% CAGR by 2036, linked to certified stroke services and structured clinical training. The USA and Japan maintain distinct growth profiles alongside UK adoption shaped by separate payment rules and hospital network organization.
Competitive Landscape	Competition spans aspiration platforms and mechanical extraction systems together with access catheters and procedural support services. Penumbra and Inari Medical address broad peripheral thrombus burdens through dedicated aspiration and mechanical thrombectomy portfolios. Medtronic and Johnson & Johnson MedTech combine neurovascular clot-removal systems with access and aspiration technologies for acute stroke care. Boston Scientific and Abbott provide peripheral systems alongside focused AngioDynamics and Philips platforms with different capital and workflow requirements.
Analyst Perspective	The commercial test is whether each system improves pathway reliability across the exact vascular condition treated. Hospitals should measure treatment preparation and clot-removal performance separately because each result has different operational causes. Procurement plans should define training and maintenance responsibilities before emergency use exposes gaps in support coverage. - Anurag Sharma, Principal Analyst at Future Market Insights

Source: FMI's proprietary forecasting model and primary research

How is the vascular thromboembolic disease thrombectomy market segmented?

The vascular thromboembolic disease thrombectomy industry is segmented by disease type, device type, procedure type, end user, and region.

The segmentation framework separates the clinical condition from the equipment and procedure selected for thrombus removal. Disease analysis covers venous and arterial events together with ischemic stroke and chronic thromboembolic disease. Device analysis distinguishes aspiration platforms from mechanical systems and hybrid technologies that combine clot disruption with evacuation. Procedure analysis compares endovascular removal with thrombolytic and fragmentation approaches across several distinct vascular beds and emergency pathways. End-user analysis separates hospitals from catheterization laboratories and specialist centers with different staffing and equipment models. Regional assessment connects neurovascular devices with local transfer networks and regulatory pathways across the covered countries.

What supports demand for Deep Vein Thrombosis within the Disease Type category?

Deep vein thrombosis creates large peripheral venous clot burdens that can require rapid escalation beyond anticoagulation alone. The current venous thromboembolism treatment landscape therefore includes device selection alongside access planning and bleeding-risk review. Commercial demand increases where vascular teams can identify suitable patients and maintain a dependable post-procedure monitoring pathway.

• In 2026, deep vein thrombosis is expected to hold 39.6% share of the disease type category, driven by established venous intervention pathways. Its position reflects the need to manage clot burden and protect venous flow across symptomatic patients selected for intervention.
• Vascular specialists adopt DVT thrombectomy systems through protocols that define imaging thresholds and adjunctive treatment choices. Hospitals gain value from platforms that support predictable clot extraction without creating unclear ownership for monitoring and follow-up.

How are Aspiration Thrombectomy Devices positioned within the Device Type category?

Aspiration systems remove thrombus through controlled suction and require catheters that remain navigable across challenging vascular anatomy. Related neurointerventional devices use aspiration within cerebral vessels but follow different indications and procedural controls. Device comparisons must therefore separate pump performance from catheter trackability and the vascular territory approved for treatment.

• By device type, aspiration thrombectomy devices are projected to represent 41.3% share in 2026, attributable to direct clot evacuation across several endovascular workflows. The share position also reflects product designs that combine aspiration control with catheters sized for specific vascular territories.
• Interventional teams favor aspiration platforms that simplify setup and provide clear feedback during clot engagement. Purchasing decisions remain sensitive to blood-loss management and compatible accessories because those factors influence total procedural reliability.

Why does Endovascular Thrombectomy lead the Procedure Type category?

Endovascular thrombectomy allows specialists to reach an occlusion through catheter-based access rather than open surgical exposure. NHS England states that eligible stroke patients should transfer without delay to a specialist mechanical thrombectomy center. The transfer requirement shows why catheter-directed thrombolysis and thrombectomy programs depend on coordinated imaging and transport pathways. Procedure demand grows where referring hospitals can activate a qualified receiving service without repeated case review or avoidable handoffs.

• Endovascular thrombectomy is forecast to account for 31.5% share in 2026, supported by minimally invasive access and targeted clot removal. Its position reflects procedural flexibility across neurovascular and peripheral cases that meet defined intervention criteria.
• Hospitals expand endovascular thrombectomy through referral agreements that specify imaging transfer and specialist acceptance responsibilities. A technically effective device cannot compensate for transport delays that prevent patients from reaching a capable treatment center.

What makes Hospitals central to the End User category?

Hospitals combine imaging and anesthesia support with specialist teams that manage complications during urgent thrombectomy procedures. The German Stroke Society updated certification criteria for stroke units during 2025 and maintains requirements for structured specialist care. Many interventional radiology services also support peripheral venous and arterial procedures through shared imaging and catheter laboratories. Hospital investment depends on procedure volume and round-the-clock readiness that justify equipment service and clinician training costs.

• Hospitals are estimated to hold 30.2% share in 2026, owing to their concentration of imaging and emergency procedural capability. The share also reflects post-procedure care requirements that are difficult to reproduce across smaller standalone treatment settings.
• Hospital committees evaluate thrombectomy equipment through pathway performance and support coverage rather than isolated catheter specifications. Systems gain wider use once nursing and imaging teams can reproduce setup steps across urgent cases and scheduled training exercises.

What are the drivers, restraints, and opportunities in the vascular thromboembolic disease thrombectomy market?

Time-sensitive vascular events support demand for effective clot removal, while service gaps and pathway delays limit routine adoption.

• Driver: Specialist teams need thrombectomy systems that restore flow through a predictable procedure during urgent vascular events.
• Restraint: Labeling errors and inconsistent training can interrupt deployment even when the underlying device remains technically capable.
• Opportunity: Better imaging coordination can identify eligible patients sooner and direct them toward the correct thrombectomy pathway.

Urgent clot-removal decisions are projected to support market growth through demand for faster treatment preparation and more consistent procedural control. NHS England reported in December 2025 that 15,377 patients received AI-supported scan review across the evaluated stroke hospitals. The same program was associated with thrombectomy rates rising from 2.3% to 4.6% across the evaluation sites. Investment in endovascular therapy devices becomes easier to defend once imaging support increases appropriate referral without weakening specialist oversight.

Operational reliability limits adoption whenever product labeling or setup guidance creates uncertainty during an emergency procedure. The FDA posted a May 2025 Class 2 recall for one Artix lot following an incorrect vessel-range statement on the label. The event concerned labeling rather than the complete platform but required affected inventory to be identified and corrected. Hospitals therefore need controlled stock records and rapid manufacturer communication that prevent avoidable disruption across urgent vascular cases.

Earlier pathway coordination creates an opportunity to treat eligible patients before clinical deterioration narrows the available intervention choices. Johnson & Johnson launched the CEREGLIDE 92 system in February 2025 to support neurovascular access during acute ischemic stroke procedures. The system expands the access toolkit used with aspiration catheters and compatible stent retrievers across complex cerebral anatomy. Commercial value grows through integrated imaging and device protocols that reduce avoidable exchanges without replacing physician case selection.

Which country CAGRs are profiled in the vascular thromboembolic disease thrombectomy market?

Country	CAGR
USA	9.0%
UK	8.1%
Germany	10.9%
Japan	9.5%
South Korea	13.2%

How do country-level CAGRs compare in the vascular thromboembolic disease thrombectomy market?

The country outlook spans a 5.1 percentage-point range between the UK and South Korea. Germany and Japan form a middle growth band with rates above the USA and UK profiles. South Korea occupies a separate upper position through its 13.2% CAGR and stronger approved growth profile. The pattern reflects different specialist networks and payment structures rather than a single regional adoption sequence.

• South Korea forms the upper growth position and remains 2.3 percentage points above Germany during the forecast period.
• Germany and Japan create the central cluster with a 1.4 percentage-point separation across their approved country forecasts.
• The USA and UK form the lower cluster while retaining positive expansion across mature hospital and reimbursement systems.
• Country rates describe the profiled outlook and do not replace local assessment of service capacity or patient transfer conditions.

Similar growth rates can produce different entry conditions across public systems and mixed hospital networks. Manufacturers must evaluate distributor support and training access alongside payment rules across each national service pathway.

Country-wise Analysis

• United States hospitals operate through large academic centers and regional referral networks with uneven access to specialist thrombectomy teams. The USA is projected to expand at 9.0% CAGR from 2026 to 2036, supported by broad device availability and established reimbursement pathways. CDC reported in January 2025 that up to 900,000 Americans experience venous thromboembolism during a typical year. Current peripheral vascular devices can reach major hospitals through direct company service and national distribution networks. Rural transfer distance remains a material friction because time-sensitive patients may begin care far from an equipped intervention center.
• United Kingdom adoption operates through NHS stroke networks and centralized specialist centers that receive patients from surrounding hospitals. The UK is forecast to record 8.1% CAGR through 2036, linked to service expansion and formal transfer pathways. NHS England reported during 2025 that a national review covered 26 mechanical thrombectomy sites and supported wider access planning. Public procurement can consolidate training and service requirements across regional networks through coordinated contracts and credentialing programs. Specialist staffing and transfer capacity remain material frictions for hospitals seeking dependable coverage during nights and weekends.
• German thrombectomy services operate through certified stroke units and neurovascular networks with formal quality and training requirements. Germany is estimated to post 10.9% CAGR by 2036, underpinned by structured specialist infrastructure and regulated clinical pathways. The German Stroke Society reported in July 2025 that its NIHSS training platform had registered 4,005 qualified healthcare professionals. National manufacturer subsidiaries and regional distributors support equipment maintenance routes across major metropolitan hospital clusters and specialist centers. Certification obligations and specialist workforce availability create material friction for smaller hospitals outside established neurovascular networks.
• Japanese stroke care combines accredited centers with strict device review and hospital purchasing processes across densely populated regions. Japan is anticipated to advance at 9.5% CAGR during the forecast period, shaped by clinical discipline and continued neurovascular technology adoption. The Japan Stroke Society released revised 2025 items for its national stroke treatment guideline on June 30. PMDA also began publishing device review summaries for qualifying applications submitted from fiscal 2025 onward. Long evaluation cycles and concentrated specialist expertise can slow broader access beyond major urban centers despite strong clinical capability.
• South Korea is expanding coordinated cardio-cerebrovascular services through regional centers and formal emergency referral responsibilities. The country is predicted to record 13.2% CAGR between 2026 and 2036, reinforced by tertiary-care capacity and fast technology evaluation. The Ministry of Health and Welfare selected ten new regional cardio-cerebrovascular disease centers during January 2025. The added centers create a direct enabler through broader access to advanced care and interhospital transfer coordination. Specialist concentration outside leading metropolitan hospitals remains a material friction for consistent national thrombectomy coverage.

Who are the notable companies in the vascular thromboembolic disease thrombectomy market?

Penumbra, Inc. and Inari Medical are notable thrombectomy companies within the defined market. Boston Scientific Corporation and Medtronic plc compete alongside Abbott Laboratories and Johnson & Johnson MedTech. AngioDynamics, Inc. and Philips Healthcare provide focused peripheral thrombectomy systems.

The competitive field combines broad thrombectomy platforms with focused peripheral and neurovascular product portfolios across several specialist treatment pathways. Penumbra remains operationally independent while its announced transaction with Boston Scientific progresses toward a stated 2026 closing. The SEC filing states that existing Penumbra contracts and partnerships remain unchanged before transaction completion. Comparisons with interventional cardiology devices help procurement teams separate vascular access support from direct thrombus-removal capability. Commercial performance depends on exact indication fit and service response rather than corporate scale across unrelated medical technology categories.

• Penumbra and Inari Medical provide dedicated aspiration and mechanical platforms across venous and peripheral arterial thrombus cases. Their portfolios support complex clot burdens through integrated catheters and purpose-built procedural components across peripheral vascular procedures.
• Medtronic and Johnson & Johnson MedTech maintain neurovascular thrombectomy portfolios that combine aspiration catheters with stent retrievers and access systems. Their competitive strength depends on complete stroke workflow compatibility across access and aspiration steps during urgent procedures.
• Boston Scientific and Abbott provide peripheral clot-removal systems through pharmacomechanical or hydrodynamic approaches across arterial and venous procedures. AngioDynamics and Philips offer aspiration platforms with different indication breadth and capital requirements across each account.

Competitive Benchmarking: Vascular Thromboembolic Disease Thrombectomy Market

Company	Thrombus Removal Breadth	Workflow Integration	Clinical Evidence Depth	Geographic Reach
Penumbra, Inc.	High	High	High	Global
Inari Medical (Stryker Corporation)	High	High	High	Global
Boston Scientific Corporation	High	High	High	Global
Medtronic plc	High	High	High	Global
Abbott Laboratories	Medium	Medium	Medium	Global
Johnson & Johnson MedTech	Medium	High	High	Global
AngioDynamics, Inc.	High	High	Medium	North America and Europe
Philips Healthcare	Medium	Medium	Low	United States and selected markets

Scoring basis: For thrombus removal breadth High covers several target vascular beds, Medium covers one broad bed, Low covers one narrow indication. For workflow integration High includes connected access and extraction components, Medium includes an integrated device and pump, Low describes a stand-alone system. For clinical evidence depth High reflects several market-specific programs, Medium reflects one established program, Low reflects documented use with limited program breadth.

Key Developments in the Vascular Thromboembolic Disease Thrombectomy Market

• In February 2025, Stryker completed its acquisition of Inari Medical and added a dedicated venous thromboembolism portfolio to its interventional business. The completed transaction changed Inari ownership while preserving the established product brand and vascular operating focus within Stryker. The acquisition gives Stryker direct participation in peripheral venous clot removal alongside its established neurovascular operations and specialist service network.
• In December 2025, Medtronic announced the first commercial use of the Liberant thrombectomy system at Mount Sinai Hospital in New York. The system is indicated for fresh soft emboli or thrombi in peripheral arterial and venous vessels. The launch broadens Medtronic participation beyond neurovascular thrombectomy into peripheral aspiration procedures across arterial and venous treatment pathways.
• In January 2026, Penumbra launched Lightning Flash 3.0 for pulmonary and venous thrombus removal through its computer-assisted vacuum thrombectomy platform. The release added enhanced clot detection and an automated backflush function for large thrombus burdens. The update strengthens Penumbra workflow control across high-volume venous thrombectomy cases that require rapid management of substantial clot burdens.
• In February 2026, Johnson & Johnson launched CEREGLIDE 42 and 57 aspiration catheters together with the INNERGLIDE 7 delivery aid. The additions completed a multi-axial aspiration-first stroke portfolio designed for distal neurovascular targets and complex vessel access. The launch expands catheter size selection across ischemic stroke thrombectomy workflows that require different aspiration and delivery profiles.

Key Players in the Vascular Thromboembolic Disease Thrombectomy Market

VTE and Peripheral Thrombectomy Systems

• Penumbra, Inc.
• Inari Medical (Stryker Corporation)
• Boston Scientific Corporation

Neurovascular and Multi-Bed Platforms

• Medtronic plc
• Johnson & Johnson MedTech
• Abbott Laboratories

Focused Peripheral Systems

• AngioDynamics, Inc.
• Philips Healthcare

Vascular Thromboembolic Disease Thrombectomy Market - Report Scope

Coverage field	Report scope
Market breakdown	Disease type, device type, procedure type, end user, and region.
Quantitative Units	USD Million
Market Definition	Devices and systems used to remove thrombus through aspiration or mechanical extraction together with pharmacomechanical action and related endovascular approaches across defined vascular diseases.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	USA, UK, Germany, Japan, and South Korea. Additional country analysis follows the complete regional framework.
Key Companies Profiled	Penumbra, Inc. and Inari Medical are profiled alongside Boston Scientific Corporation and Medtronic plc. Abbott Laboratories and Johnson & Johnson MedTech are also profiled. AngioDynamics, Inc. and Philips Healthcare complete the company group.
Forecast Period	2026 to 2036.
Approach	Hybrid bottom-up and top-down market sizing supported by structured industry consultation and authoritative desk research.

Vascular Thromboembolic Disease Thrombectomy Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Vascular Thromboembolic Disease Thrombectomy Market by Segments

Vascular Thromboembolic Disease Thrombectomy Market segmented by Disease Type:

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Acute Limb Ischemia
• Stroke (Ischemic)
• Chronic Thromboembolic Disease

Vascular Thromboembolic Disease Thrombectomy Market segmented by Device Type:

• Aspiration Thrombectomy Devices
• Mechanical Thrombectomy Devices
• Catheter-Directed Thrombolysis Systems
• Hybrid Pharmacomechanical Systems

Vascular Thromboembolic Disease Thrombectomy Market segmented by Procedure Type:

• Endovascular Thrombectomy
• Catheter-Directed Thrombolysis
• Aspiration-Based Removal
• Mechanical Fragmentation

Vascular Thromboembolic Disease Thrombectomy Market segmented by End User:

• Hospitals
• Cardiac Catheterization Labs
• Interventional Radiology Centers
• Specialty Vascular Centers

Vascular Thromboembolic Disease Thrombectomy Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• USA Food and Drug Administration. (2025, May 14). 510(k) Premarket Notification: Symphony Thrombectomy System (K250775).
• USA Food and Drug Administration. (2025, June 11). 510(k) Premarket Notification: Liberant Thrombectomy System (K250787).
• Centers for Disease Control and Prevention. (2025, January 27). Data and Statistics on Venous Thromboembolism.
• NHS England. (2025, December 2). “Life-changing” AI support helping stroke patients get a second chance.
• NHS England. (2025, February 6). Operational performance update.
• NHS England. (2025, April 4). 2025/26 NHS Payment Scheme - Annex C: Guidance on best practice tariffs.
• Boston Scientific Corporation. (n.d.). ANGIOJET Peripheral Thrombectomy System.
• Abbott. (n.d.). JETi Hydrodynamic Thrombectomy System: Important Safety Information.
• USA Food and Drug Administration. (2025, May 6). Class 2 Device Recall Artix MT Thrombectomy Device.
• Johnson & Johnson. (2025, February 12). Johnson & Johnson MedTech Launches CEREGLIDE 92 Catheter System for Acute Ischemic Stroke.
• Deutsche Schlaganfall-Gesellschaft. (2025). Zertifizierungskriterien für Stroke-Units in Deutschland: Update 2025.
• Deutsche Schlaganfall-Gesellschaft. (2025, July 30). Ein Jahr NIH-Schlaganfall-Skala: Großer Erfolg für DSG-Schulungsplattform.
• The Japan Stroke Society. (2025, June 30).2025〕 [Japanese Guidelines for the Management of Stroke 2021, revised 2025].
• Pharmaceuticals and Medical Devices Agency. (n.d.). [Overview of medical device reviews].
• Ministry of Health and Welfare, Republic of Korea. (2025, January 16).[Ten new regional cardio-cerebrovascular disease centers selected].
• USA Securities and Exchange Commission. (2026, January 16). Penumbra transaction communications filed under Rule 425.
• Stryker. (2025, March 6). Inari Medical, now part of Stryker, launches Artix Thrombectomy System.
• Stryker. (2025, February 19). Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment.
• Medtronic. (n.d.). Acute Ischemic Stroke Revascularization Products.
• Medtronic. (2025, December 10). Medtronic announces successful early commercial use of Liberant thrombectomy system.
• Penumbra, Inc.. (2026, January 26). Penumbra Launches Lightning Flash 3.0: The Next Evolution in CAVT Technology.
• Johnson & Johnson. (2026, February 26). Johnson & Johnson Completes Catheter Portfolio with Launch of CEREGLIDE 42, CEREGLIDE 57, and INNERGLIDE 7.
• AngioDynamics. (n.d.). AlphaVac Mechanical Thrombectomy System.
• Philips. (n.d.). QuickClear quick brochure.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the vascular thromboembolic disease thrombectomy market in 2026 and 2036?
• Which clinical and operating conditions support the 10.7% CAGR through 2036?
• Why does deep vein thrombosis hold the largest disease type share during 2026?
• How do aspiration thrombectomy devices shape purchasing decisions across vascular services?
• Why does endovascular thrombectomy lead the procedure type category during 2026?
• How do country growth rates differ across the USA, UK, Germany, Japan, and South Korea?
• Which companies provide direct thrombectomy systems within the defined market boundary?
• What service and pathway constraints can limit routine adoption across hospital networks?
• How should hospitals compare product breadth, workflow integration, and clinical evidence depth?